Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Atomo Diagnostics Ltd. ( (AU:AT1) ) has provided an announcement.
Atomo Diagnostics Ltd. has reported significant growth in its HIV Self-Test business, highlighted by a $230k order for the national scale-up of the CONNECT Programme in Australia and a product launch in New Zealand through Chemist Warehouse. The company also secured an exclusive license for a novel syphilis test, supported by a $2.44 million grant from the Commonwealth Government, which will aid in further analytical testing and commercial discussions.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. operates in the medical diagnostics industry, focusing on the development and supply of rapid diagnostic test devices. The company is primarily known for its HIV Self-Test products and is expanding its market presence in developed regions, including Australia and New Zealand.
Average Trading Volume: 450,155
Technical Sentiment Signal: Buy
Current Market Cap: A$12.78M
For detailed information about AT1 stock, go to TipRanks’ Stock Analysis page.